Total Funding
35
43
Total FundingSeries A raised
Growth Score
1 pts
Heat Score
-1 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
84698
Asylia Therapeutics is a biotech company focused on novel immune-modulating therapies for autoimmune, cancer, and infectious diseases.
- Jeno Gyuris: Executive Vice President and Chief Scientific OfficerPast Role: AVEO Oncology, Chief Scientific Officer
Ronald A. DePinho: Co-Founder & Co-ChairPast Role: Eden Therapeutics, Co-Founder and Director
About the Company
Asylia Therapeutics is a biotech company focused on novel immune-modulating therapies for autoimmune, cancer, and infectious diseases.
The company's platform centers on a drug pipeline capable of modulating antigen presentation to the immune system which has produced unprecedented anti-tumor responses across multiple cancer models.
Asylia
Therapeutics was founded in 2019 in Houston, Texas.
